Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
about
Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioningNovel agents and biomarkers for acute lymphoid leukemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest ChinaLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantatiUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaPharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Current and future management of Ph/BCR-ABL positive ALL.Targeting FLT3 to treat leukemia.Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.A review of blinatumomab, a novel immunotherapy.The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party oIndividualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.Inhibition of FLT3 in AML: a focus on sorafenib.Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Continuing challenges and current issues in acute lymphoblastic leukemia.Advances in adult acute lymphoblastic leukemia therapy.Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation.Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia.Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
P2860
Q26795740-7B50060B-6011-49CA-A126-47A42E87CFA9Q26829775-3977E21F-9178-427B-AA6E-15EE4F06C642Q27025242-540DAF5A-30EC-4EDD-AD1A-996218FD584AQ30243925-3D445E62-26B2-405D-B582-3A8F19D612A7Q33822032-A86657FC-1964-4D1F-BA49-F7E88E1C3BEAQ34380489-6101EBFF-BDDC-4E69-98F0-F0B9FA0D5485Q34532041-95BC2D3E-1AAC-4B3F-99B7-A2D73B2D5CC6Q35100974-7B590EB0-31EA-4744-9261-52AD289D2D18Q35146312-B74E870C-BD20-4E87-82D2-F1F0B9DA6BFDQ35731623-9EC4658E-BBA2-4664-A9AA-1F012898EE10Q35888941-687003CC-52BC-45C6-AE2A-F5C814BCE13EQ36338763-B1E02FA5-577C-47B3-AC2A-9AAE4BFE1086Q37555821-92ADE292-D4EF-4EC5-AFD5-E6C784D9A7DDQ37564762-362130B8-9FFA-497E-9659-74084DF8F13EQ37632798-38DA18A8-3E29-4DD2-9531-43DC2080CF2DQ37702242-71CB3CE3-6BF2-4859-ADDB-9BE1621D03B2Q38133244-3A08A825-F29F-46DA-9E5D-99B899924955Q38194585-B0CE9C13-BBD7-48A5-A1CB-7A0FF67BE459Q38251339-3CA625D7-A830-4E79-BB69-30EFF5AB6384Q38452047-1AD20899-4F48-4738-911C-9AB1F037FD48Q38647682-A51F7C10-6A1A-417C-BC35-70FDA1FB713DQ38674733-645DCB72-48C6-4D98-8610-4B8225A9C1E5Q38698520-6B4E91C6-9AFF-442C-9D3F-6965FFE2F53DQ38777538-82E8A7F2-A22E-43AE-8C56-660E75E04188Q38863489-D35430C6-C22C-4C25-91AE-A5AF24C8803CQ38866851-56054DCB-09C0-4D6C-A8E0-AA748C89DE78Q38897538-49EDDD28-8EB5-4085-B8E2-8D91CE189D52Q38989349-A489B80D-174E-42F6-B0CF-515A2D2F848CQ39022777-3279BFC9-0722-41B2-A15A-71FEF929EAE3Q39307476-73F642DD-6D37-427B-B9A8-12697C76439FQ39366299-07BF7336-736D-4D58-AB3E-890A4EB44C3EQ39459190-91823B66-5779-4DA1-A98E-88DC6B3FAA6BQ40122841-2CA055A7-1B89-4AC1-AC3E-B4C5924A8C17Q40422304-BCBADC29-D67A-4579-9752-E7303E24CC2DQ40519372-3FDF3D0E-E248-45D1-9BC9-BCC4FFCA4EE7Q41715958-2201DB47-9C1F-4025-B592-B9D52935448BQ42325811-FD0A3851-440A-4E27-A378-8950163DDAFFQ42609684-0E4963FC-0509-490F-B6B9-1E8CED823A78Q42650776-755B25FA-42D2-4676-9928-70FC10002BCBQ43175147-639E0F35-76DC-4FD9-8B77-E719CF98AE1D
P2860
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@en
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@nl
type
label
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@en
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@nl
prefLabel
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@en
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Randomized comparison of proph ...... acute lymphoblastic leukemia.
@en
P2093
B Kubuschok
B Wassmann
GMALL Study Group
P2860
P2888
P304
P356
10.1038/LEU.2012.352
P577
2012-12-05T00:00:00Z